RedditBluesky
  • Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
Home » News » Morphosys' Pelabresib: New shine after setback

Morphosys' Pelabresib: New shine after setback

Stock Rises and Hope for Myelofibrosis Patients Thanks to Promising Phase 3 Results

Scott Wright (SW)October 4, 2026



The German biotech company Morphosys recently published promising results from a phase 3 study involving its hopeful pelabresib. This cancer drug plays a crucial role for the company and its future prospects. The study examined the effect of a combination of pelabresib and ruxolitinib, the current standard therapy for the rare malignant bone marrow disease myelofibrosis, compared to a placebo in combination with ruxolitinib. The results, announced by Morphosys on Monday, show significant improvement in all disease characteristics.

Investors reacted extremely positively to this news, and Morphosys shares rose by an impressive twelve percent to just under 28 euros at the start of trading. This meant that the losses that the company had to accept in November due to disappointing study data were fully compensated. Nevertheless, the price is still well below the annual high of 32.45 euros reached in September.

The gloomy outlook caused the Morphosys share price to plunge by more than 30 percent on November 21, when the expected study data on pelabresib failed to convince investors. Although the main goal of the study was achieved, the drug was only able to adequately improve the symptoms of the disease, which was an important secondary goal of the study.

However, the latest results from the Phase 3 study, presented at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, have now given investors hope again. The study showed significant improvements in all four key features of myelofibrosis, which include spleen size, anemia, bone marrow fibrosis and disease-related symptoms. Raajit K. Rampal, director of the Center for Hematologic Malignancies and the Myeloproliferative Neoplasms Program at Memorial Sloan-Kettering Cancer Center, emphasized the significance of the findings. Reducing the size of the spleen is particularly important because it is linked to patient survival. In addition, the study showed that the combination of pelabresib and ruxolitinib was not only well tolerated but also effective in treating anemia, disease-related symptoms and bone marrow fibrosis.

Morphosys acquired pelabresib through the takeover of US cancer specialist Constellation Pharma for $1.7 billion and plans to apply for approval of the drug in the US and Europe next year. The promising results of this phase 3 study could initiate a paradigm shift in the treatment of myelofibrosis and set the company on a successful path in cancer drug development. Investors are once again optimistic and Morphosys' future appears brighter than ever.

Pharmaindustrie





Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


Claw and Order: Antimony Rules the Resource Realm
Read Next

Claw and Order: Antimony Rules the Resource Realm

  • RIDE THE BULL

    Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

  • Trending Now

    • Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
      Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
    • Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
      Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
    • Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama
      Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama
    • How Ameriwest Is Funding Its Bornite Copper Exploration Through Portfolio Optimization
      How Ameriwest Is Funding Its Bornite Copper Exploration Through Portfolio Optimization

Claim Your Spot with Juniorstocks.com

Unlock the stories that move markets directly in your inbox


ContactDisclaimerData PrivacyTerms of Use
  • Bluesky
  • Reddit
Copyright 2026 ©Juniorstocks.com - All Rights Reserved.